scholarly journals Programmed cell death ligand 1 and tumor‐infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation

Cancer ◽  
2017 ◽  
Vol 123 (24) ◽  
pp. 4823-4831 ◽  
Author(s):  
Fumi Kawakami ◽  
Kanishka Sircar ◽  
Jaime Rodriguez‐Canales ◽  
Bryan M. Fellman ◽  
Diana L. Urbauer ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Tumor Infiltrating Lymphocyte

scholarly journals Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma

2020 ◽  
Vol 3 (5) ◽  
pp. 176-179 ◽  
Author(s):  
Yoko Maegawa ◽  
Taigo Kato ◽  
Shinichiro Fukuhara ◽  
Hiroshi Kiuchi ◽  
Ryoichi Imamura ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Experienced Patient ◽  
Programmed Cell Death 1

scholarly journals Durable Remission with Immunotherapy in a Patient with Sarcomatoid Renal Cell Carcinoma

2021 ◽  
Vol 8 (4) ◽  
pp. 38-42
Author(s):  
Nwabundo Anusim ◽  
Damilola Gbadebo ◽  
Olabisi Afolayan-Oloye ◽  
Ishmael Jaiyesimi
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Therapy Response ◽  
Histologic Subtype ◽  
Attractive Option ◽  
Sarcomatoid Renal Cell Carcinoma ◽  
Sarcomatoid Differentiation

Sarcomatoid differentiation is a rare and aggressive histologic subtype with poor prognosis, seen in several malignancies. In sarcomatoid renal cell carcinoma (RCC), the degree of sarcomatoid differentiation and the stage at presentation determines the prognosis. Despite resection, chemotherapy and targeted therapy response is modest, with relapse usually occurring within a few months. We present a case of a gentleman with sarcomatoid RCC managed with pembrolizumab, who has had no evidence of recurrence for over 4 years since the last dose of immunotherapy. RCCs with sarcomatoid differentiation have a high presence of programmed cell death protein 1 and programmed cell death ligand 1 in T cells and tumor cells, respectively, making immunotherapy an attractive option in this setting. Clinical trials are ongoing to further define the benefit of immunotherapy in sarcomatoid RCC.

Atezolizumab-induced type 1 diabetes mellitus in a patient with metastatic renal cell carcinoma

2020 ◽  
Vol 13 (7) ◽  
pp. e233842 ◽  
Author(s):  
Wedad Rahman ◽  
Anna Conley ◽  
Kristi D Silver
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Death ◽  
Type 1 Diabetes ◽  
Programmed Cell Death ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Checkpoint Inhibitor ◽  
Autoimmune Reaction

Checkpoint inhibitor immunotherapy has revolutionised cancer treatment since its inception. During an inflammatory response, activated cytotoxic T cells expressing programmed cell death protein 1 (PD-1) interact with programmed cell death-ligand 1 (PD-L1) on peripheral tissues to thwart an autoimmune reaction. Cancer cells upregulate PD-L1 expression to evade the immune system and are vulnerable to attack in the presence of PD-1 or PD-L1 checkpoint inhibitors. However, blockade of this pathway also contributes to the unintended side effect of autoimmune endocrinopathies. Atezolizumab, a checkpoint inhibitor against PD-L1, is associated with the rare complication of type 1 diabetes. We present a case of glutamic acid decarboxylase antibody-positive type 1 diabetes developing in a patient with a long-standing history of well-controlled type 2 diabetes following treatment with atezolizumab for metastatic renal cell carcinoma.

scholarly journals Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma

2018 ◽  
Vol 7 (4) ◽  
pp. e1413519 ◽  
Author(s):  
Kyu Seo Kim ◽  
Rishi R. Sekar ◽  
Dattatraya Patil ◽  
Michelle A. Dimarco ◽  
Haydn T. Kissick ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Prognostic Biomarker ◽  
Cell Renal Cell Carcinoma ◽  
Cell Death Protein
Sign in / Sign up

Export Citation Format

Share Document